<DOC>
	<DOCNO>NCT00033813</DOCNO>
	<brief_summary>This study help determine safety efficacy mast cell stabilizer Oxatomide treatment Duchenne muscular dystrophy ( DMD ) . Boys DMD enrol study take steroid treat DMD least twelve month , take nutritional supplement least three month . Subjects complete two screen visit within one-week period , enrol strength test monthly three month begin therapy Oxatomide . Once Oxatomide therapy start , participant strength test monthly six month . Following six month treatment period , participant give option remain Oxatomide study complete .</brief_summary>
	<brief_title>KUL0401 : An Open-label Pilot Study Oxatomide Steroid-Naive Duchenne Muscular Dystrophy</brief_title>
	<detailed_description />
	<mesh_term>Muscular Dystrophies</mesh_term>
	<mesh_term>Muscular Dystrophy , Duchenne</mesh_term>
	<mesh_term>Oxatomide</mesh_term>
	<criteria>Subject Inclusion Criteria 1 . 5 10 year age 2. ambulatory 3. diagnosis DMD confirm least one following : Positive xlinked family history DMD old male relative ( onset 5 year , wheelchair bound 12 year ) , ; Dystrophin immunofluorescence and/or immunoblot show complete dystrophin deficiency , clinical picture consistent typical DMD , ; Gene deletion test positive ( miss one exon ) central rod domain ( exon 2560 ) dystrophin , read frame predict 'out frame ' , clinical picture consistent typical DMD . 4. glucocorticosteroidnaive ( i.e . treat prednisone deflazacort within past year ) 5 . Evidence muscle weakness MRC score clinical functional evaluation 6 . QMT biceps score variability great 10 % screen visit Subject Exclusion Criteria 1 . Failure achieve one inclusion criterion list 2 . Inability suitably cooperate strength assessment 3 . Symptomatic DMD carrier 4 . Use oxatomide ( antihistamine drug ) within last 6 month DMD disease 5 . Use creatine monohydrate glutamine within last 6 month 6 . Use carnitine , Coenzyme Q10 , amino acid herbal medication within last 3 month 7 . History symptomatic cardiomyopathy 8 . History impairment hepatic function 9 . History significant concomitant illness significant impairment renal function .</criteria>
	<gender>Male</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>10 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Duchenne</keyword>
	<keyword>muscular</keyword>
	<keyword>dystrophy</keyword>
	<keyword>control clinical trial</keyword>
	<keyword>CINRG</keyword>
</DOC>